Novartis suffers a loss in its fight to block Regenxbio's Zolgensma patent extension
Novartis came up short on Wednesday in its bid to block its tiny biotech partner Regenxbio from getting a patent term extension (PTE) on Zolgensma.
The Swiss pharma giant uses Regenxbio’s AAV9 vector for its blockbuster spinal muscular atrophy drug, which brought in more than $1.3 billion last year alone. But the company’s gene therapies unit told the FDA in August that Regenxbio shouldn’t have filed for a PTE last April because that application should have come from Novartis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free.